KemPharm, Inc. (NASDAQ:KMPH) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

KemPharm, Inc. (NASDAQ:KMPH) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
Item 5.02Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

Story continues below

(e)

2017 Cash Bonus Payouts

OnJanuary 25, 2018, the Compensation Committee (the "Compensation Committee") of the Board of Directors (the “Board”) of KemPharm, Inc., a Delaware corporation (the "Company"),approved the payment of cash bonuses to the Company’s named executive officers and principal financial officer (the “Executive Officers”) based on the achievement in 2017 of corporate and individual goals previously approved by the Board.The amounts awarded to the Executive Officers were as follows:

Executive Officer and Principal Position

Bonus Amount

Travis C. Mickle, Ph.D.

$

136,000

President and Chief Executive Officer

Sven Guenther, Ph.D.

$

65,688

Executive Vice President, Research and Development

Daniel L. Cohen

$

66,640

Executive Vice President, Government and Public Relations

R. LaDuane Clifton, CPA

$

61,880

Chief Financial Officer, Secretary and Treasurer

2018 Base Salaries and Cash Bonus Plan TargetPayouts

OnJanuary 25, 2018, the Compensation Committeeapproved the 2018 base salaries and target bonus awards forthe Executive Officers. The 2018 bonus awards for the Executive Officers will bebased on the achievement of corporate and individual goals,as approved by the Board.The 2018 basesalaries and target bonus awards for the Executive Officersare as follows:

Executive Officer and Principal Position 2018 Base Salary Bonus Target (1)
Travis C. Mickle, Ph.D. $ 515,000 50%
President and Chief Executive Officer
Sven Guenther, Ph.D. $ 355,000 35%
Executive Vice President, Research and Development
Daniel L. Cohen $ 350,000 35%
Executive Vice President, Government and Public Relations
R. LaDuane Clifton, CPA $ 335,000 35%
Chief Financial Officer, Secretary and Treasurer
(1) Bonus Targets listed as percentage of 2018 Base Salary


About KemPharm, Inc. (NASDAQ:KMPH)

KemPharm, Inc. is a clinical-stage specialty pharmaceutical company. The Company is engaged in the discovery and development of prodrugs. The Company uses its Ligand Activated Therapy (LAT) platform technology to create prodrugs. The Company’s product candidate, KP201/APAP, consists of KP201, its prodrug of hydrocodone, which is combined with acetaminophen (APAP). The Company is developing KP201/APAP as an immediate release (IR), a product candidate for the short-term, or no longer than 14 days for the management of acute pain. The Company has designed KP201/APAP with abuse-deterrent properties to address the epidemic of opioid abuse in the United States. The Company also focuses on developing the pipeline of additional prodrug product candidates that targets pain and attention deficit hyperactivity disorder (ADHD). The Company’s products include KP201/IR (APAP-free), KP511/ER, KP415, KP606/IR and KP746.

An ad to help with our costs